Satoru Kakizaki

88PUBLICATIONS
162CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biochemistry - proteins and peptides (incl. medical proteomics)Cancer therapy (excl. chemotherapy and radiation therapy)Chiropractic
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (88)

|Oct 05, 2026
Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab.

|Sep 23, 2026
Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy.

|Sep 16, 2026
Trends in the Proportion of Hepatitis C Virus Antibody-Positive Patients Who Could be Considered for Direct-Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real-World Cohort Study in Japan.

|Sep 15, 2026
Prognostic Value of the FIB-3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis.

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Pageof 15

Frequent Collaborators

58 joint publications

Takeshi Hatanaka

50 joint publications

Atsushi Naganuma

33 joint publications

Hidenori Toyoda

33 joint publications

Toshifumi Tada